What is NKTR's market cap?

$1.23B, based on the Nov 5 close of $36.15.

Does Nektar Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of NKTR is sold short?

7.0M shares, 21.0% of float, as of Oct 15, 2026.

What sector is NKTR in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · NKTRHealthcarePharmaceuticals

Nektar Therapeutics (NKTR)

$36.15−6.06%

Close Nov 5, 2026 · split-adjusted

Nov 5, 2026$36.15▼ 33.38% in range

Nov 5, 2025Low $35.12 · High $100.35Nov 5, 2026

What changed · written from our data

As of Nov 5, 2026

Nektar Therapeutics closed at $36.15 on Nov 5, down 6.06%, within 2.9% of its 52-week closing low. Volume of 729.4K shares was 0.87× its 20-day average (close to normal).

Split-adjusted performance: -10.2% over one month, -56.6% over six months, -35.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $10.13M, down 9.3% from a year earlier, with a net margin of -401.0%.

Short interest was 7.0M shares at the Oct 15 settlement (21.0% of float, 3.5 days to cover).

Market cap$1.23B34.1M shares

Revenue · quarter$10.1M−9.3% YoY

Diluted EPS$-1.23—

P/E · TTM—P/S 22.6×

Net margin-401.0%Gross 100.0%

Dividend yieldNone

52-week range35.12 – 100.35−64.0% from high

Volume729.4K0.87× 20-day avg

Volatility · 60d70.7%Annualised

Short % of float21.0%3.5 days to cover

Net cash$684.3MCash $684.3M

Next earnings—Not scheduled

Split-adjusted performance

1W −7.7%1M −10.2%3M −52.7%6M −56.6%YTD −14.5%1Y −35.5%3Y +413.9%5Y −85.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum21

Revenue growth34

Net margin32

Value (low P/E)—

Size73

Industry medians: 6-month return −28.4%, revenue growth +5.9%, net margin −38.9%, P/E 15.0×.

Short interest

Details →

Shares short7.0M+0.4% vs prior

Days to cover3.5Settled Oct 15

% of float21.0%

Short vol. 10d52.3%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
NKTRNektar Therapeutics	$36.15	−6.06%	−56.6%	−9.3%	−401.0%	—	$1.23B
OMEROmeros	$17.07	−6.11%	+16.6%	—	46.4%	9.9	$1.24B	Compare
LBRXLB Pharmaceuticals	$38.09	−6.76%	+19.1%	—	—	—	$1.23B	Compare
MNKDMannkind	$3.76	−4.33%	+5.9%	+42.9%	−17.4%	—	$1.21B	Compare
URGNUroGen Pharma	$25.73	−10.47%	−3.2%	+199.2%	−19.8%	—	$1.26B	Compare
AVLNAvalyn Pharma	$26.67	−2.91%	—	—	—	—	$1.18B	Compare
AMPHAmphastar Pharmaceuticals	$27.66	−1.28%	+15.1%	+5.4%	16.5%	15.0	$1.18B	Compare
KARDKardigan	$13.86	−10.93%	—	—	—	—	$1.30B	Compare
OPKOpko Health	$1.75	−1.13%	+56.3%	+4.3%	−5.1%	—	$1.31B	Compare

News about Nektar Therapeutics

All news →

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research · Oct 29, 2026▲ Positive Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?Zacks Investment Research · Oct 15, 2026Neutral What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 LaunchThe Motley Fool · May 23, 2026▲ Positive Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc. · May 5, 2026▼ Negative NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Enrollment Protocol Compliance: Levi & KorsinskyGlobeNewswire Inc. · May 5, 2026▼ Negative

Quick answers

What does Nektar Therapeutics do?: Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes.
What is NKTR's market cap?: $1.23B, based on the Nov 5 close of $36.15.
Does Nektar Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of NKTR is sold short?: 7.0M shares, 21.0% of float, as of Oct 15, 2026.
What sector is NKTR in?: Healthcare, in the Pharmaceuticals industry.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

HQ: San Francisco, CA63 employeesListed May 3, 1994nektar.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology